Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 4
2006 1
2007 4
2008 2
2009 4
2010 7
2011 2
2012 4
2013 4
2014 1
2015 3
2017 7
2018 4
2019 8
2020 14
2021 15
2022 17
2023 10
2024 10
2025 15
2026 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Bardia A, et al. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282896 Clinical Trial.
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Cortés J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. Cortés J, et al. N Engl J Med. 2025 Nov 13;393(19):1912-1925. doi: 10.1056/NEJMoa2511734. Epub 2025 Oct 19. N Engl J Med. 2025. PMID: 41124233 Clinical Trial.
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.
Rinnerthaler G, Egle D, Bartsch R, Schmitt CA, Petzer A, Balic M, Petru E, Denison U, Singer CF, Bjelic-Radisic V, Gampenrieder SP, Knauer M, Sotlar K, Brunner C, Posch F, Hlauschek D, Sölkner L, Bago-Horvath Z, Filipits M, Gili M, Ritter M, Wieser V, Albertini C, Zaborsky N, Weiss L, Marhold M, Schneeweiss B, Pusch R, Gnant M, Greil R. Rinnerthaler G, et al. Among authors: balic m. Nat Cancer. 2025 Jan;6(1):41-50. doi: 10.1038/s43018-024-00890-2. Epub 2025 Jan 16. Nat Cancer. 2025. PMID: 39820125 Free PMC article. Clinical Trial.
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: bc.overview@ndph.ox.ac.uk; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: bc.overview@ndph.ox.ac.uk, et al. Lancet. 2025 Aug 9;406(10503):603-614. doi: 10.1016/S0140-6736(25)01013-X. Lancet. 2025. PMID: 40783288 Free article.
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
Bartsch R, Singer CF, Pfeiler G, Hubalek M, Stoeger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Muy-Kheng TM, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Bartsch R, et al. Among authors: balic m. Br J Cancer. 2021 May;124(11):1795-1802. doi: 10.1038/s41416-021-01284-2. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762716 Free PMC article. Clinical Trial.
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdóttir Á, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Montoya ML, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ. Aftimos P, et al. Among authors: balic m. Cancer Discov. 2021 Nov;11(11):2796-2811. doi: 10.1158/2159-8290.CD-20-1647. Epub 2021 Jun 28. Cancer Discov. 2021. PMID: 34183353 Free PMC article.
The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy.
Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA; ADAPT Consortium. Bild AH, et al. Cancer Cell. 2026 Mar 9;44(3):449-454. doi: 10.1016/j.ccell.2025.12.008. Epub 2026 Jan 8. Cancer Cell. 2026. PMID: 41512871 Free PMC article.
It is time to prepare for D-CARE!
Suppan C, Balic M. Suppan C, et al. Among authors: balic m. Ann Transl Med. 2020 Nov;8(21):1339. doi: 10.21037/atm-2020-99. Ann Transl Med. 2020. PMID: 33313084 Free PMC article. No abstract available.
Expert Discussion: ASCO 2022.
Balic M, Wimmer K, Suppan C, Silovski T, Brunner C. Balic M, et al. Breast Care (Basel). 2022 Aug;17(4):430-436. doi: 10.1159/000525966. Epub 2022 Jul 8. Breast Care (Basel). 2022. PMID: 36156916 Free PMC article. No abstract available.
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko JM, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon KA, Goetz M, Haddad TC, Iwata H, Jassem J, Lee SC, Linderholm B, Los M, Mamounas EP, Miller KD, Morris PG, Munzone E, Gal-Yam EN, Ring A, Shepherd L, Singer C, Thomssen C, Tseng LM, Valagussa P, Winer EP, Wolff AC, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck AC, DeMichele A, Gnant M; PALLAS Groups and Investigators. Pfeiler G, et al. Among authors: balic m. J Clin Oncol. 2023 Nov 20;41(33):5118-5130. doi: 10.1200/JCO.23.00126. Epub 2023 Aug 9. J Clin Oncol. 2023. PMID: 37556775 Clinical Trial.
131 results